sufentanil sublingual 30 mcg tablet
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Moderate-to-severe Acute Pain
Conditions
Moderate-to-severe Acute Pain
Trial Timeline
Oct 1, 2015 → Jul 1, 2016
NCT ID
NCT02447848About sufentanil sublingual 30 mcg tablet
sufentanil sublingual 30 mcg tablet is a phase 3 stage product being developed by Talphera for Moderate-to-severe Acute Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT02447848. Target conditions include Moderate-to-severe Acute Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02447848 | Phase 3 | Completed |
Competing Products
13 competing products in Moderate-to-severe Acute Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine | Pacira Biosciences | Approved | 80 |
| Tildrakizumab + Placebo + Tildrakizumab + Tildrakizumab + Tildrakizumab + Etanercept + Placebo | Sun Pharmaceutical | Phase 2/3 | 65 |
| SHR-1314 | Jiangsu Hengrui Medicine | Phase 1 | 33 |
| SHR-1314 + Placebo | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| SHR-1314 + Placebo | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| Indacaterol + Control | Novartis | Phase 3 | 77 |
| Deucravacitinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Dupilumab + Placebo | Sanofi | Phase 3 | 76 |
| dupilumab | Sanofi | Approved | 84 |
| dupilumab | Sanofi | Pre-clinical | 22 |
| Ponesimod | Vanda Pharmaceuticals | Phase 3 | 69 |
| sufentanil sublingual tablet 30 mcg | Talphera | Phase 3 | 69 |
| Zalviso™ 15 mcg | Talphera | Phase 3 | 69 |
Other Products from Talphera
sufentanil sublingual tablet 30 mcgPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + morphine IV PCAPhase 3
69
Zalviso™ 15 mcgPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemPhase 3
69
Sufentanil NanoTab PCA System/15 mcg + Placebo Sufentanil NanoTab PCA SystemPhase 3
69